Physicians' Academy for Cardiovascular Education

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD - Bridgend, Wales, UK

Video navigation menu

  • RAASi therapy is the cornerstone treatment for HF, CKD and T2D 00:22
  • Suboptimal RAASi therapy following a hyperkalemic event 01:33
  • Practical experience with SZC for the optimization of RAASi in HFrEF 02:44
  • Model for the prescribing and monitoring of SZC in HF therapy 06:38
  • Conclusions 08:24


Show transcript

Educational information

This lecture by Aaron Wong, MD was part of the EBAC-accredited symposium "Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy" held at the ESC Congress 2023, Amsterdam, The Netherlands.


Aaron Wong, MD is a consultant cardiologist and general physician working at the Princess of Wales Hospital, Bridgend, South Wales, United Kingdom. He is the local heart failure lead, and also works as a local principal investigator.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.


Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.

Find here the slides of the presentation Watch the other videos of this series

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: